Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib in PSA Recurrence After Radiation or Prostatectomy
NCT00073970Phase 2Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Apr 2003
- Primary completion
- Jun 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib in prostate cancer (PCa), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Effect of COX-2 inhibitors on PSA level at 9 months. Started Apr 2003; status: terminated.
02
Drugs
celecoxib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00073970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073970.